Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in Unresectable or Metastatic Melanoma
NCT04356729Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Aug 2020
- Primary completion
- Jun 2026
- Countries
- 1
- Modality
- Monoclonal Antibodies
- Conditions
- cutaneous melanoma (CM)
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in cutaneous melanoma (CM). Primary endpoint: Overall Response Rate at 5 years. Started Aug 2020; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Atezolizumab and Bevacizumab
Experimental arm receiving Atezolizumab and Bevacizumab intravenously every 3 weeks.
03
Who it enrols
Adults with metastatic or unresectable stage III/IV cutaneous melanoma that is PD-L1 negative, with measurable disease, adequate organ function, and ECOG <= 2. Excludes patients with active CNS metastases, autoimmune disease, HIV, active HBV/HCV, or prior anti-PD-L1/bevacizumab therapy.
04
Endpoints
Primary
Overall Response Rate
Secondary
Overall Survival
Time to Tumor Progression
Duration of Response
Treatment-Related Adverse Events
Change in Tumor-Infiltrating Lymphocytes
Beyond the preview
Go deeper on NCT04356729.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356729.